462 related articles for article (PubMed ID: 12632340)
21. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
22. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor.
Middeke M; Hoffmann S; Hassan I; Wunderlich A; Hofbauer LC; Zielke A
Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):386-92. PubMed ID: 12518248
[TBL] [Abstract][Full Text] [Related]
24. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
25. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
Gabrilovich DI; Ishida T; Nadaf S; Ohm JE; Carbone DP
Clin Cancer Res; 1999 Oct; 5(10):2963-70. PubMed ID: 10537366
[TBL] [Abstract][Full Text] [Related]
26. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.
Kondo S; Asano M; Suzuki H
Biochem Biophys Res Commun; 1993 Aug; 194(3):1234-41. PubMed ID: 7688963
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine.
Albini A; Morini M; D'Agostini F; Ferrari N; Campelli F; Arena G; Noonan DM; Pesce C; De Flora S
Cancer Res; 2001 Nov; 61(22):8171-8. PubMed ID: 11719447
[TBL] [Abstract][Full Text] [Related]
28. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Fox WD; Higgins B; Maiese KM; Drobnjak M; Cordon-Cardo C; Scher HI; Agus DB
Clin Cancer Res; 2002 Oct; 8(10):3226-31. PubMed ID: 12374693
[TBL] [Abstract][Full Text] [Related]
29. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.
Wei LH; Kuo ML; Chen CA; Chou CH; Lai KB; Lee CN; Hsieh CY
Oncogene; 2003 Mar; 22(10):1517-27. PubMed ID: 12629515
[TBL] [Abstract][Full Text] [Related]
31. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
Yukita A; Asano M; Okamoto T; Mizutani S; Suzuki H
Anticancer Res; 2000; 20(1A):155-60. PubMed ID: 10769648
[TBL] [Abstract][Full Text] [Related]
32. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
33. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.
Cooke SP; Boxer GM; Lawrence L; Pedley RB; Spencer DI; Begent RH; Chester KA
Cancer Res; 2001 May; 61(9):3653-9. PubMed ID: 11325835
[TBL] [Abstract][Full Text] [Related]
34. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.
Bagri A; Berry L; Gunter B; Singh M; Kasman I; Damico LA; Xiang H; Schmidt M; Fuh G; Hollister B; Rosen O; Plowman GD
Clin Cancer Res; 2010 Aug; 16(15):3887-900. PubMed ID: 20554752
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
36. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
37. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
Luo JC; Toyoda M; Shibuya M
Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process.
Barbera-Guillem E; Nyhus JK; Wolford CC; Friece CR; Sampsel JW
Cancer Res; 2002 Dec; 62(23):7042-9. PubMed ID: 12460925
[TBL] [Abstract][Full Text] [Related]
39. [Experimental study of anti-vascular endothelial growth factor hairpin ribozyme gene inhibiting growth of xenografted tumor of ovarian cancer cells].
Yan R; Xin X; Jin M; Hui H; Wang J; Wang D
Zhonghua Fu Chan Ke Za Zhi; 2002 Nov; 37(11):683-6. PubMed ID: 12487926
[TBL] [Abstract][Full Text] [Related]
40. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
